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Key Clinical Message
We successfully immunized the neonatal-onset multisystem inflammatory dis-
ease (NOMID) patient with live-attenuated vaccines for measles, rubella, vari-
cella, and mumps and achieved sufficient antibody titer under canakinumab
therapy without complications.
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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a peri-
odic fever syndrome classified as an autoinflammatory dis-
ease [1–3]. CAPS is caused by abnormalities in the NLRP3
protein in which a genetic mutation in the NACHT
domain causes continuous overproduction of interleukin
(IL)-1b, resulting in chronic inflammation and progressive
tissue damage [4–7]. Canakinumab is a fully humanized
anti-IL-1b monoclonal antibody that has been successfully
used to manage CAPS [8–10]. However, clinical trials of
canakinumab have been carried out in patients aged
2 years or older [11]. Furthermore, while the efficacy and
safety of canakinumab have been recently reported [8–15],
few reports have described administration of this drug in
infants [16, 17]. Despite the lack of studies, data have
highlighted the importance of beginning early treatment
in infancy to prevent irreversible organ damage and life-
long disabilities in patients with CAPS.
Inoculation of live-attenuated vaccines is contraindi-
cated in patients treated with biologic agents. Therefore,
live-attenuated vaccines should be administered before
initiating the treatment. However, neither live-attenuated
vaccines nor biologics are recommended in early infancy.
Herein, we present the case of a 4-month-old girl with
CAPS who exhibited neonatal-onset multisystem inflam-
matory disease/chronic infantile neurologic, cutaneous,
and articular (NOMID/CINCA) syndrome. In this case,
we successfully treated the patient with canakinumab
starting at 6 months of age and immunized the patient
with live-attenuated vaccines for measles, rubella, varicella,
and mumps, without the occurrence of adverse events.
Case Presentation
We acquired approval for this case study from the ethics
committee of Toho University Hospital (no. 25-1, 26-148,
and 27-137). Written informed consent was obtained
from the guardians of the patient for publication of this
case report and any accompanying images.
The 4-month-old girl was admitted to our hospital
because of a generalized urticarial rash. She was born via
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spontaneous vaginal delivery at 38 weeks of gestation to a
healthy 39-year-old mother after an uncomplicated preg-
nancy. At birth, her weight was 2340 g (1.5 SD) and
her length was 46 cm (1.1 SD). The rash appeared
immediately after birth and worsened 4 months later;
thus, the patient was referred to our hospital.
On the first visit to our outpatient clinic, the patient
showed a high inflammatory response upon laboratory
blood examination, although she was afebrile. One day
before admission for further examination, the patient’s
temperature rose to 38°C and a daily fever recurred there-
after. There was no family history of skin rash, periodic
fever, or other autoinflammatory diseases.
Physical examination showed an urticarial rash measur-
ing 10–20 mm in diameter surrounded by erythema gen-
erally distributed over the skin. Audiography assessments
did not show any abnormalities, with no joint swelling;
however, hematological and serum biochemical examina-
tions revealed a white blood cell count of 17,300/lL, with
a differential profile of 5.5% band neutrophils, 30.5% seg-
mented neutrophils, and 61% lymphocytes; C-reactive
protein (CRP) was 59 mg/L; erythrocyte sedimentation
rate (ESR) was 38 mm/h; serum amyloid A (SAA) was
251 lg/mL (control ≤ 8); serum IL-6 was 67.6 pg/mL
(control ≤ 4); serum immunoglobulin (Ig) G was
1.127 mg/dL; IgA was 25 mg/dL; and IgM was 126 mg/
dL. Tests for autoantibodies were negative. A virological
test showed a positive cytomegalovirus (CMV) IgM titer
of 3.82 (control < 0.8) and a positive CMV IgG titer of
30.9 (control < 2.0), whereas CMV-C7HRP and CMV
antigenemia were negative; these data indicated a recent
CMV infection. The skin biopsy for histopathological
examination showed no eosinophilic infiltration, with
mild perivascular neutrophil infiltration.
After hospitalization, periodic fevers, aseptic meningitis,
and a skin biopsy provided strong indicators of an
autoinflammatory disease. An informed consent was
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Figure 1. Growth and development of the patient. The patient exhibited normal growth and development after the initiation of canakinumab
treatment, with no signs of mental retardation. Mean and standard deviations of height, weight, and head circumference are shown for 0–
27 months of age. B.Ht., B.Wt, and H.C. indicate body height, body weight, and head circumference, respectively.
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testing, which showed a de novo heterozygous mutation
in the NLRP3 gene (c.2263G > A, p.Gly755Arg heterozy-
gous); this mutation has been reported as a CAPS dis-
ease-causing mutation [18].
Accordingly, we started the patient on canakinumab at
6 months old after acquiring approval from the institu-
tional ethics committee (no. 25-1) of our hospital. A pos-
itive clinical response was noted, with complete
disappearance of the skin rash and periodic fevers 8.5 h
after the first injection (2 mg/kg). The patient met the
clinical and serological remission criteria used in the Japa-
nese clinical studies [11], and canakinumab was adminis-
tered as a single 2 mg/kg dose once every 8 weeks via
subcutaneous injection.
Outcome and Follow-Up
Thereafter, the patient’s body weight rapidly increased
and motor development progressed normally (Fig. 1). She
began to walk at 15 months old and demonstrated nor-
mal psychomotor development.
We detected the presence of Streptococcus pneumoniae
and Branhamella catarrhalis at 13 months old and Hae-
mophilus influenzae type B at 15 months old using a suc-
tion sputum culture. These pathogens occasionally cause
acute bronchopneumonia and acute bronchitis; however,
they did not cause severe infection in this patient. In
contrast, adenovirus-induced acute bronchopneumonia
and norovirus-induced gastroenteritis resulted in the
patient requiring intravenous treatment for several days
(Fig. 2).
Nevertheless, the patient experienced periodic fevers
without rash starting at 20 months old, with an elevated
CRP of 32 mg/L and SAA of 349 lg/mL. After diagnosing
her relapse, we increased the therapeutic dose of canaki-
numab in a stepwise manner to 6 mg/kg within 6–
7 weeks (Fig. 2). The patient is now 47 months old and
in clinical and serological remission.
Figure 2. Clinical course and laboratory findings after the initiation of canakinumab therapy. The figure shows the serum amyloid A (SAA) profile
during the canakinumab treatment period. The disease-causing pathogens and diseases are underlined. Inoculation with live-attenuated vaccines
(MR v., VZV v., and mumps v. are measles–rubella vaccine, varicella zoster vaccine, and mumps vaccine, respectively) are indicated by solid
arrows.
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Because viral infections may have triggered or exacer-
bated the CAPS symptoms, we implemented a normal
vaccine schedule; the patient was vaccinated with Bacillus
Calmette–Guerin (BCG), Haemophilus influenzae type B
(Hib), 13-pneumococcal polysaccharide vaccine (PCV13),
and diphtheria–pertussis–tetanus-inactivated polio vaccine
(DPT-IPV) before initiating treatment (Table 1). Addi-
tionally, we administered the seasonal influenza vaccine
and palivizumab for respiratory syncytial virus (RSV)
infection. We then proposed a clinical research project to
immunize the patient with live-attenuated vaccines while
under canakinumab treatment, which was approved by
the ethics committee of our hospital (no. 26-148, 27-137).
Thus, the patient received the measles–rubella (MR) vac-
cine, primary/booster varicella zoster virus (VZV) vacci-
nes, and mumps vaccine 3–4 weeks after the last injection
and 4 weeks before the next injection of canakinumab at
31–46 months of age. She had no vaccine-related adverse
effects and achieved sufficient antibody titers (measles IgG
titer of ≥128 [control < 2.0]; rubella IgG titer of 31.5
[control < 2.0]; varicella zoster IgG titer of 6.0 [primary],
26.6 [booster; control < 2.0]; and mumps IgG titer of 7.8
[primary], 48.0 [booster; control < 2.0]; Table 1).
Discussion
NOMID/CINCA syndrome is the most severe CAPS phe-
notype [12], exhibiting major symptoms such as chronic
aseptic meningitis, developmental delays, mental retarda-
tion, osteoarthropathy, sensorineural hearing loss, and
optic neuritis with loss of vision if left untreated [13]. We
herein report a case of NOMID syndrome that was effec-
tively and safely treated with canakinumab starting at
6 months of age without severe complications. In
addition, we successfully immunized the patient with live-
attenuated vaccines.
Because canakinumab is not approved for use in
infants younger than 2 years, we initiated treatment after
acquiring approval from the institutional ethical commit-
tee of our hospital and the patient’s parents. We also
found three reports of infants treated with canakinumab;
however, these cases had not been described in the litera-
ture at the initial presentation of our case [13, 16, 17].
Although the treatment in these three cases appeared to
be effective with no particular or severe adverse effects,
higher dosages of canakinumab were needed to control
the disease [9, 10, 12]. Moreover, these reports high-
lighted the importance of beginning treatment early in
infancy to prevent irreversible organ damage and lifelong
disability. A minimum dose of canakinumab was main-
tained for remission in the present case until 20 months
of age. The treatment was entirely effective and safe.
Treatment of genetic disorders, such as CAPS, at
infancy may result in complications with vaccinations.
However, nonlive vaccines are generally safe and effective
in pediatric patients with autoimmune and rheumatic dis-
eases receiving corticosteroids, immunosuppressants, and
biologics [19–22]. Recently, the safety and efficacy of live-
attenuated vaccines in rheumatic and autoimmune dis-
eases have also been reported [23–26]. However, these
findings are not sufficient to support the safety and
immunogenicity of live-attenuated vaccines in pediatric
patients with autoimmune and rheumatic diseases. Thus,
live-attenuated vaccines should be administered to these
patients only after acquiring approval from the appropri-
ate institutional review board.
Autoinflammatory diseases are rare, making it difficult
to perform studies with large numbers of patients. To
Table 1. Immunization records and antibody titers after vaccinations.
Before treatment After treatment
Age (months) Vaccine Frequency Antibody titer Age (months) Vaccine Frequency Antibody titer
2–4 Hib 3 12 Hib 1
2–4 PCV13 3 12 PCV13 1
3–4 DPT-IPV 3 Pertussis FHA 27 17 DPT-IPV 1 Pertussis FHA 29
4 BCG 1 31 MR 1 Measles ≥128
Rubella 31.5
37 VZV① 1 VZV 6
44 VZV② Booster VZV 26.6
42 Mumps① 1 Mumps 7.8
46 Mumps② Booster Mumps 48.0
12–37 Flu 6
Hib, Haemophilus influenzae type B; PCV13, pneumococcus; DPT-IPV, diphtheria–pertussis–tetanus-inactivated polio vaccine; FHA, filamentous
hemagglutinin; MR, measles–rubella; VZV, varicella zoster virus; BCG, Bacillus Calmette–Guerin.
IgG antibody titers of measles, rubella, and varicella viruses were measured by enzyme-linked immunosorbent assay (ELISA) (Control < 2.0).
Filamentous hemagglutinin (FHA) in Bordetella pertussis IgG antibody titers was measured by ELISA (Control < 10.0 EU/mL).
The names in bold type indicate live vaccines.
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date, only seven patients have been described as receiving
live-attenuated vaccines along with antitumor necrosis
factor alpha (TNF-a) treatment; no reports have
described the use of live-attenuated vaccines in patients
administered anakinra and rilonacept. Five patients
received the measles–mumps–rubella (MMR) vaccine, and
two patients received the VZV vaccine without severe
adverse events. Moreover, very few cases of patients
receiving canakinumab therapy and the MMR vaccine
have been reported to date; indeed, only one case in
which vaccines were accidentally administered is currently
described in the literature [9].
Vaccine schedules are different for each country. In
Japan, an MR booster and varicella vaccine were included
in the national vaccine program in 2006 and 2014, respec-
tively. However, as the mumps vaccine is still optional, it
is possible that our patient will be exposed to chickenpox
and mumps while in school. Further, it is likely that viral
infections exacerbated the initial CAPS symptoms, result-
ing in delayed treatment. In addition, our hospital is near
an international airport. Thus, the patient was at risk of
contact with individuals having infectious diseases
acquired abroad; several measles outbreaks have occurred
in recent years. Considering the risk of contracting vac-
cine-preventable diseases and the report of successful
MMR immunization of a CAPS patient on canakinumab
[9], we successfully immunized our patient with live-atte-
nuated MR, varicella, and mumps vaccines without any
side effects. Subsequently, we administered VZV and
mumps booster vaccines and obtained sufficient titers.
As described above, canakinumab appears to be effec-
tive and safe in infants with NOMID/CINCA syndrome.
In the present case, we started treatment early to avoid
irreversible sequelae. Moreover, we successfully immu-
nized the patient with live-attenuated vaccines concomi-
tantly with canakinumab treatment. Thus, a normal
vaccination schedule may be possible in these patients to
avoid acquiring vaccine-preventable diseases. Accordingly,
further studies of live-attenuated vaccines in these
patients are urgently needed to improve their quality of
life.
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